FutureFemHealth’s Post

Gameto expands into Australia with a partnership with #IVF clinic chain, IVFAustralia (IVFA) part of the Virtus Health group. 🇦🇺🇦🇺 Under this partnership, Gameto’s product, Fertilo, will be available for patients at select IVFA/Virtus clinics. The Virtus Health clinic network is one of the top 5 assisted reproductive services providers in the world. 👶👶 Fertilo is a solution derived from induced pluripotent stem cells (iPSC) and designed to mature eggs outside the body as part of minimal hormonal stimulation cycles for IVF and egg freezing. This replaces 80% of hormone injections required with traditional IVF. 🩼🩼 #stemcells #biotech #fertility #IVF #iPSC Read the release: 👇👇

🔬 World’s first live birth using eggs matured outside the body successful In a world-first, a live human birth that used an ovarian support cell (OSC) technology that matures eggs outside the body has been successful. Unlike traditional IVF methods, which rely on 10 to 14 days of high-dose hormonal stimulation to mature eggs, this new method – named Fertilo – uses engineered, young ovarian support cells to recreate the natural egg maturation process in a laboratory setting. This process replaces 80% of hormone injections required with traditional IVF, and reduces the duration of treatment cycles to just three days, offering patients a more comfortable and less invasive experience. 💬 Dr Dina Radenkovic Turner, CEO and co-founder of Gameto which has developed the technology, said: “By overcoming the major challenges of conventional IVF, such as long treatment cycles, significant side effects, and the emotional and physical strain, Fertilo provides a potentially faster, safer, and more accessible solution for families. "This milestone marks a turning point in reproductive health and highlights the first application of iPSC technology in IVF and the immense potential of our technology.” Read more: https://lnkd.in/eE-uwWbB #womenshealth #womenshealthmatters #femtech #healthtech #genderhealthgap #research #innovation #healthequity #gynaecology #reproductivehealth #equalities #healthinequalities #women #medtech

Gameto just announced the world's first live birth using stem cell technology that allows eggs to mature outside of the body. This process replaces 80% of the hormone injections required for traditional IVF, and minimizes risks of ovarian hyperstimulation syndrome and other side effects of high hormone doses. This is a hugely promising advancement and could revolutionize the IVF process for women already suffering from infertility and undergoing multiple painful treatments and procedures. #IVF #infertility #Fertilo

The IVF market is projected to grow at a robust rate of 9% by 2029. For more detailed insights, get your sample report here: https://lnkd.in/dxBNGQf4 Several factors are driving this growth, including: 👉Increasing median age of first-time mothers 👉Technological advancements in IVF devices 👉Growing IVF tourism 👉Rising number of fertility clinics worldwide 👉Declining fertility rates 👉Increasing cases of male infertility 👉Favorable funding environment Leading players in this market include CooperCompanies, Vitrolife, Thermo Fisher Scientific, Esco Medical, IVFtech ApS, FUJIFILM Irvine Scientific, Kitazato, FertiPro N.V., Gynotech Ltd., and more.

"Exploring the Future of IVF in Australia: Unique Trends Shaping the Market in 2024" 𝐌𝐚𝐫𝐤𝐞𝐭 𝐕𝐚𝐥𝐮𝐞 : The Australian IVF Services Market was valued at USD 526.82 million in 2023 and is projected to grow at a CAGR of 3.5% from 2023 to 2030, reaching approximately USD 670.26 million by 2030. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 : The in-depth analysis of the Australian IVF Services market highlights key factors shaping the industry, including regulatory, financial, and ethical aspects. Despite limited public funding, private IVF clinics are thriving due to rising demand, creating opportunities for growth, mergers, and acquisitions. 𝑪𝒍𝒊𝒄𝒌 𝒉𝒆𝒓𝒆 𝒇𝒐𝒓 𝒇𝒓𝒆𝒆 𝒔𝒂𝒎𝒑𝒍𝒆 + 𝒓𝒆𝒍𝒂𝒕𝒆𝒅 𝒈𝒓𝒂𝒑𝒉𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒓𝒆𝒑𝒐𝒓𝒕:  https://lnkd.in/dwybxqjR 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬 : The dynamics of the Australian IVF Services market are shaped by a combination of rising demand, limited public funding, and growing technological advancements. With increasing awareness around fertility options, more patients are seeking treatments like genetic testing, egg freezing, and pre-implantation genetic diagnosis (PGD). 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 : The Australian IVF Services market is experiencing key trends driven by technological advancements, shifting patient preferences, and evolving healthcare policies. Fertility treatments such as egg freezing, genetic testing, and pre-implantation genetic diagnosis (PGD) are gaining popularity, reflecting a growing demand for personalized and advanced reproductive options. 𝑼𝒏𝒍𝒐𝒄𝒌 𝒚𝒐𝒖𝒓 𝒆𝒙𝒄𝒍𝒖𝒔𝒊𝒗𝒆 𝑷𝑫𝑭 𝒏𝒐𝒘!  https://lnkd.in/dA3keqxg 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐠𝐢𝐨𝐧 : The Australian IVF Services market is characterized by regional variations, with major hubs of fertility treatment concentrated in metropolitan areas such as Sydney, Melbourne, and Brisbane. These regions see the highest demand due to greater access to advanced technologies, specialized clinics, and comprehensive fertility services. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 : Virtus Health Monash IVF Group IVF Australia Genea #AustraliaIVF #IVFServices #FertilityCare #FertilityAustralia #IVFMarket #IVFTrends #FertilityJourney #ReproductiveHealth #IVFInnovation #EggFreezing #GeneticTesting #FertilityTreatment #AustralianHealthcare #IVFClinics #FertilityAwareness #PreimplantationGeneticTesting #PGD

Study data presented at the American Society for Reproductive Medicine suggests that common treatments for advanced-stage endometriosis, dienogest (a progestin) and triptorelin (a GnRH agonist), may negatively impact IVF outcomes. Findings showed lower birth rates for women treated with these medications compared to a control group with no treatment before IVF, sparking questions on their effectiveness. Though the study's small sample size warrants cautious interpretation, it highlights a need for further investigation into alternative approaches for endometriosis-associated infertility. Read more in this article from MedPage Today: https://bit.ly/3A8krGl Visit Heranova.com to learn more about endometriosis and HerResolve, our non-invasive, blood-based diagnostic solution for endometriosis detection. #Heranova #HerResolve #WomensHealth #ASRM24

The world’s first baby has been born using Gameto's Fertilo technology – a revolutionary method that reduces IVF hormone injections by 80%! 👶 Back in 2023, Extend Fertility partnered with Gameto to help research this game-changing technology for IVF and fertility care, so it's incredible to witness this historical moment! “This breakthrough brings new hope to families everywhere,” said Gameto’s CEO Dr. Dina Radenkovic Turner Fertilo is an induced pluripotent stem cell (iPSC) derived proprietary solution for IVF and egg freezing that matures eggs outside of the body, using a reduced stimulation protocol that decreases most side effects associated with the traditional protocol. Not only is this the first-ever live birth using Fertilo, but it also marks the first-ever human birth due to iPSC technology. Fertilo allows eggs to mature outside the body, shortening treatment cycles from 10-14 days to 3 days. This means: 💉 Fewer hormone injections ⏱️ Shorter treatment times ☺️ Less physical & emotional strain Congratulations to the entire Gameto team on this historic breakthrough in IVF! What are your thoughts on this game-changing fertility innovation? ✨ Article information pulled from Femtech Insider ✨ Learn more about Gameto on their website : gametogen.com ✨ Review our cutting-edge research study on our website here: https://lnkd.in/e98DcBFB Read the full article on Femtech Insider here: /https://lnkd.in/eqm7-dY2

𝐓𝐫𝐞𝐧𝐝𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐧 𝐕𝐢𝐭𝐫𝐨 𝐅𝐞𝐫𝐭𝐢𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐞𝐭 𝐞-𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐟𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨@https://lnkd.in/dMNc-drN The global In Vitro Fertilization Market size was worth around USD 19.62 billion in 2022 and is predicted to grow around USD 33.93 billion by 2032, with a compound annual growth rate of roughly 6.2% between 2023 and 2032. IVF is an important infertility treatment and is widely used as assisted reproductive technology treatment. Over the past few decades, the advances in IVF have made this method of impregnation very popular with patients and doctors, and in terms of availability and cost, it has become easier even in low- and middle-income countries. Technological advances in IVF have exceeded imagination with the cryopreservation of surplus embryos. The North America market is the dominating market owing to the prevalence of co-diseases such as polycystic ovary syndrome (PCOS) and government support for sperm and egg storage is contributing to market expansion. In the U.S., IVF success rates for women under 35 rose slightly overall in 2020, with 47.2% of cycles ending in one child, compared to women over 40 who used their eggs and embryos, where 7.2% of cycles resulted in live births. In addition, recently opened fertility centers and fertility compensation practices are driving the demand for infertility treatments, among others. #ivfmarket,#fertilitytrends,#reproductivehealth,#infertilitysolutions,#ivftechnologies,#fertilitycare,#embryotechnology,#assistedreproduction

"Australia IVF Services: A Growing Market for Reproductive Healthcare" 𝐌𝐚𝐫𝐤𝐞𝐭 𝐕𝐚𝐥𝐮𝐞 : In 2023, the Australia IVF Services Market was valued at USD 526.82 million and is projected to grow at a CAGR of 3.5% from 2023 to 2030, reaching approximately USD 670.26 million by 2030. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 : The comprehensive analysis of the Australian IVF Services market highlights key factors shaping the industry, including regulatory, financial, and ethical considerations. Private IVF clinics continue to thrive despite limited public funding and increasing demand, creating opportunities for growth, mergers, and acquisitions. 𝑪𝒍𝒊𝒄𝒌 𝒉𝒆𝒓𝒆 𝒇𝒐𝒓 𝒇𝒓𝒆𝒆 𝒔𝒂𝒎𝒑𝒍𝒆 + 𝒓𝒆𝒍𝒂𝒕𝒆𝒅 𝒈𝒓𝒂𝒑𝒉𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒓𝒆𝒑𝒐𝒓𝒕: https://lnkd.in/dwybxqjR 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬 : The Australian IVF Services market is experiencing significant transformation driven by rising demand for fertility treatments and a surge in private clinic operations. Valued at USD 526.82 million in 2023, the market is projected to grow at a CAGR of 3.5%, reaching approximately USD 670.26 million by 2030. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 : The Australia IVF Services market is witnessing transformative trends that are reshaping the fertility landscape. With a market valuation of USD 526.82 million in 2023, it is poised for substantial growth at a CAGR of 3.5%, reaching nearly USD 670.26 million by 2030. Key trends include the increasing adoption of advanced fertility treatments like preimplantation genetic diagnosis (PGD), egg freezing, and genetic testing, reflecting a growing emphasis on personalized care. 𝑼𝒏𝒍𝒐𝒄𝒌 𝒚𝒐𝒖𝒓 𝒆𝒙𝒄𝒍𝒖𝒔𝒊𝒗𝒆 𝑷𝑫𝑭 𝒏𝒐𝒘! https://lnkd.in/dA3keqxg 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐠𝐢𝐨𝐧 : The Australia IVF Services market is a rapidly evolving sector, significantly impacting the regional healthcare landscape. Valued at USD 526.82 million in 2023, the market is set to grow at a CAGR of 3.5%, reaching nearly USD 670.26 million by 2030. The increasing prevalence of fertility challenges and the rising demand for advanced reproductive technologies are driving this growth. #AustraliaIVF #HealthcareInnovation #MarketInsights #FertilitySupport #ReproductiveHealth #FamilyBuilding #IVFCommunity #IVFTrends #FertilityInnovation #AustraliaHealthcare #MarketGrowth #PatientCare #HealthcareTrends #FamilyPlanning